LEGION CONSO(02129) issues positive profit prediction, expecting a mid-term profit attributable to shareholders of approximately 700,000 Singapore dollars, turning losses into profits compared to the same period last year.

16:33 12/08/2026

LEGION CONSO (02129) announced that it expects to achieve a profit attributable to owners of the company of about 700,000 Singapore dollars for the six months ending June 30, 2026 (the current period), compared to a loss attributable to owners of the company of about 1.56 million Singapore dollars for the six months ending June 30, 2025 (the previous period). The anticipated turnaround to profitability is mainly due to (i) an increase in customer demand for truck transport services and freight forwarding services during the current period, driving revenue growth; and (ii) a decrease in professional fees, resulting from a decline in consulting and advisory costs compared to the previous period.

LEGION CONSO (02129) announced that it expects to achieve a profit attributable to the company's owners of approximately SGD 700,000 for the six months ending June 30, 2026 (the current period), compared to a loss attributable to the company's owners of approximately SGD 1.56 million for the six months ended June 30, 2025 (the previous period). The anticipated turn from loss to profit is primarily due to (i) an increase in customer demand for truck transportation services and freight forwarding services during the current period, driving revenue growth; and (ii) a reduction in professional fees, as consulting and advisory costs have decreased compared to the previous period.

ORIENTAL EXPL (00430) issues a profit warning, expecting that integrated profit attributable to shareholders for the first half of the year will decrease to approximately HK$3 million to HK$3.2 million.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-7590 injection has obtained the Drug Clinical Trial Approval Notification.

CHINA RES LAND (01109) reported a cumulative contract sales amount of approximately 130.6 billion yuan for the first seven months, an increase of 5.7% year-on-year.